Paul Mead
Paul Mead
CorFlow Therapeutics
Develops the CoFI System, a medical device that diagnoses microvascular obstruction (MVO) in real-time during percutaneous coronary interventions (PCI) using existing guide catheters and wires. It provides rapid, accurate detection of MVO, a condition affecting up to 60% of acute heart attack patients, and enables controlled delivery of therapeutic agents directly into the vasculature to improve patient outcomes.
- Hardware
- Healthcare Technology
- Medical Devices
Updated 7 months ago
Funding
Raised to date
$73.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Microvascular obstruction (MVO) is a frequent complication, occurring in up to 60% of acute heart attack patients, where small blood vessels in the heart become blocked, potentially leading to tissue death and adverse outcomes. Current methods for detecting MVO, such as cardiac magnetic resonance (CMRI), are not routinely utilized early in the management of acute heart attack patients. Failure to detect and treat MVO can lead to re-hospitalization with heart failure or other major adverse cardiac events.
Solution
CorFlow's Controlled Flow Infusion (CoFI) System is designed to diagnose MVO in real-time during percutaneous coronary interventions (PCI) using existing guide catheters and wires. The CoFI System rapidly delivers microvascular diagnostic information, seamlessly fitting into the PCI workflow. It also enables controlled delivery of therapeutic agents directly into the vasculature. By accurately detecting MVO and providing a platform for targeted drug delivery, the CoFI System aims to improve cardiac patient outcomes and expand physician treatment capabilities.
Target Audience
The primary users are interventional cardiologists and medical professionals involved in the treatment of acute heart attack patients undergoing PCI procedures.
Features
- Real-time MVO detection during PCI procedures.
- Utilizes existing guide catheters and wires for seamless integration into the PCI workflow.
- Rapid delivery of microvascular diagnostic information in minutes.
- Controlled and safe infusion of pharmaceutical or therapeutic agents directly into the vasculature.
- Aims to accurately detect MVO compared to the gold standard CMRI.